Kevin Brennan - 01 Jan 2024 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
SVP, FINANCE AND ACCOUNTING
Signature
/s/ Julia Walcott, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
01 Jan 2024
Transactions value $
$0
Form type
4
Filing time
03 Jan 2024, 16:15:25
Previous filing
18 Aug 2023
Next filing
03 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Restricted Stock Units Award $0 +20K $0.00 20K 01 Jan 2024 Common Stock 20K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F2 These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028.